Special Issue

Clinical Development in Multiple Sclerosis Diagnosis and Treatment

Message from the Guest Editor

Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease that continues to challenge clinicians and researchers alike. Recent years have seen a surge in our understanding of the pathogenesis and treatment options for MS, yet there is still much to be uncovered. The application of humoral, clinical, or digital biomarkers to detect early onset or monitor disease progression has become commonplace. A biomarker precisely reflecting the inflammatory and degenerative components of MS would allow for therapies to be exactly adapted, reducing delays in treatment optimization. The call for robust molecular and cellular biomarkers to evaluate MS therapies is more urgent than ever. This Special Issue focuses on enhancing our understanding and advancing the field of MS through innovative research on biomarkers. We are inviting original research articles and reviews that explore: Pharmacogenomics and Proteomics in MS, Systems Biology in MS, Omics Association Analysis in MS and Clinical Development of MS Biomarkers.

Dr. Majid Ghareghani

Guest Editor

Dr. Majid Ghareghani

Neuroscience Laboratory, CHU de Québec Research Centre, Department of Molecular Medicine, Faculty of Medicine, Laval University, Québec City, QC G1V 4G2, Canada

Deadline for manuscript submissions

closed (31 January 2024)

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:
indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:
CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).